[BidClub_]

PERSON DIRECTORY

Sarah Guo

Host of No Priors. Sarah Guo appears in 71 indexed conversations across No Priors, Invest Like the Best, Latent Space. This directory brings every appearance, source, TL;DR, digest, and transcript into one searchable feed.

71 EPISODES3 SHOWS
11 episodes2 active
Language
No PriorsEN · 43 min

Re-Founding Incumbents for the AI Era with Sequence Holdings Co-Founder and CEO Michael Lee

Sarah GuoMichael Lee

Sequence Holdings is pairing frontier engineering with incumbent advantages, partnering with the Dell family office on its $7.7B acquisition of Baldwin.At BankSouth, average consumer-loan underwriting volume fell 94%, timelines dropped from 30 days to 11, and Q2 loan volume doubled versus Q1 without changed standards.Whether Atlas can repeat that operating leverage depends less on code than on the more difficult human engineering problem.

Invest Like the BestEN · 60 min

Sarah Guo - What the 250 People Building AI Believe - [Invest Like the Best, EP.489]

Patrick O'ShaughnessySarah Guo

Sarah Guo says competitive open-source AI is already widespread, so US restrictions could handicap law-abiding American businesses while adversaries ignore them.Her roughly 250-person network sees recursive self-improvement and “some sort of exponential intelligence” as a one-to-two-year possibility, while Sunday Robotics targets home-robot beta by year-end.Compute independence, regulation, and physical supply chains remain constraints, while Chai Discovery’s $10 million contract and customer adoption test AI’s ability to capture value in biology.

No PriorsEN · 39 min

Chasing Trillion-Dollar Companies, Founder Ambition, Token Budgets, & Regulatory Capture

Sarah GuoElad Gil

Anthropic, OpenAI, and SpaceX’s leap toward $1 trillion is a five-year anomaly, while reaching that scale likely requires $50 billion-$100 billion of revenue with good margins.AI’s opportunity may be far larger than current per-seat models imply, but compute bottlenecks, founder exit timing, recursive-self-improvement uncertainty, and token allocation by return on invested tokens remain decisive constraints.

No PriorsEN · 45 min

Re-engineering the Semiconductor Supply Chain with Intel CEO Lip Bu Tan

Sarah GuoElad GilLip-Bu Tan

Lip-Bu Tan’s Intel turnaround starts with faster accountability, balance-sheet repair and product simplification, while inference and agentic AI could lift CPU demand from one per eight GPUs toward one per four or one per one.Intel Foundry remains a costly trust and supply-chain bet against TSMC, with IP, yield and cycle time as the proof points; its potential may surface around 2030–2032 as packaging, power and materials become harder bottlenecks.

No PriorsEN · 41 min

From SaaS to AI-First: How Companies Are Reshaping Innovation

Sarah GuoElad Gil

The “SaaSpocalypse” overgeneralizes a real shift: Decagon and Sierra show support moving from per-seat software toward usage-priced agents, while products such as Samsara retain hardware, distribution, enterprise sales, and support moats.GPT-4-equivalent pricing fell 150x in 21 months as Gil’s team puts AI labs’ growth from $1 billion to $10 billion at roughly a year, shifting the bottleneck to trustworthy human review and defenses against one- to two-year displacement cycles.

No PriorsEN · 76 min

NVIDIA’s Jensen Huang on Reasoning Models, Robotics, and Refuting the “AI Bubble” Narrative

Sarah GuoElad GilJensen Huang

Reasoning, search grounding, and confidence routing have made tokens valuable enough for customers to pay, while AI factories expand demand for chips, energy, construction, electrical, networking, and technical labor.Falling inference costs, open-source research, programmable hardware, and vertical specialists challenge permanent frontier concentration, but industrial deployment still requires reliability approaching 99.99999%; energy capacity, export controls, robotics adoption, and sustained demand will test NVIDIA’s anti-bubble thesis.

No PriorsEN · 41 min

No Priors Ep. 144 | The 2026 AI Forecast with Sarah & Elad

Sarah GuoElad Gil

AI adoption is “blinding” among doctors, lawyers, and compliance teams, even as a weak Nvidia quarter could trigger panic; verticals such as coding, medical scribing, and legal software such as Harvey are consolidating.Monitor robotics timeline slippage and whether an AI IPO becomes a reflexive benchmark trade; Sarah forecasts somebody will make “hundreds of millions of dollars trading markets with LLMs” in 2026.

No PriorsEN · 58 min

Jared Kushner: BrainCo, Affinity Partners, and the Geopolitics of AI

Jared KushnerSarah GuoElad Gil

Affinity Partners seeks returns through governance judgment, networks, and hands-on execution, while favoring Gulf and Latin American tailwinds and contrarian opportunities such as Albania.BrainCo is productizing reusable AI infrastructure for institutions, with a permitting workflow reduced from over 40 steps to 35 at over 90% accuracy; adoption, talent, project selection, and energy permitting remain key constraints.

No PriorsEN · 28 min

No Priors Ep. 109 | With Sarah and Elad

Sarah GuoElad Gil

Image generation is entering another quality shock, but controllability and seamless vertical workflows matter more commercially than novelty alone.As foundation-model capabilities and product surfaces converge, distribution, consumer surplus, and specialized opportunities in physics, materials, robotics, science, health, and biology become more important.Defensibility depends on proprietary data-generation engines or genuinely different technical theses, while MCP, capital availability, and the next model release could quickly reshape today’s emerging market structure.

No PriorsEN · 41 min

No Priors Ep. 104 | With Flagship Pioneering CEO and Co-Founder Noubar Afeyan

Sarah GuoNoubar Afeyan

Noubar Afeyan’s Flagship Pioneering model treats parallel startup creation as a repeatable institution for underwriting uncertainty, using variation, selection and iteration rather than forecasting breakthroughs.Generate Biomedicines has more than 15 computationally designed antibody programs, but Phase III trials, FDA regulation, pricing power and platform funding remain decisive constraints, as Joule’s technically successful but economically unviable outcome demonstrates.